Romain Altwegg

Université de Montpellier — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index4.1kcitations226works7.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(151), Microscopic Colitis(89), Immunodeficiency and Autoimmune Disorders(29), Autoimmune and Inflammatory Disorders(23), Diagnosis and treatment of tuberculosis(20)

Publications218 total

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID
Journal of Crohn s and Colitis·2025
Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis
Clinical Gastroenterology and Hepatology·2025· 3 citedOpen Access
A randomized controlled trial of antibiotics targeting adherent and invasive <i>Escherichia coli</i> versus placebo in Crohn’s disease: the TEOREM trial
Journal of Crohn s and Colitis·2025· 2 cited
Effectiveness and Safety of a Second <scp>JAK</scp> Inhibitor in Ulcerative Colitis: The <scp>J2J</scp> Multicentre Study
Alimentary Pharmacology & Therapeutics·2025· 9 citedOpen Access
PErsistence and Safety of Subcutaneous Infliximab 1 Year After Switch From Intravenous Route in IBD Patients in REMission
Clinical Gastroenterology and Hepatology·2025· 3 citedOpen Access
Anal cancer and Crohn’s disease: be careful to fistulas!
Hépato-Gastro & Oncologie Digestive·2025
Tu1837: EFFECTIVENESS COMPARISONS BETWEEN TOFACITINIB, FILGOTINIB AND UPADACITINIB IN ULCERATIVE COLITIS: RESULTS FROM THE JAKARTA REAL-WORLD EVIDENCE MULTICENTER STUDY
Gastroenterology·2025
Safety of Advanced Combination Treatment With Selective <scp>JAK1</scp> Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience
Alimentary Pharmacology & Therapeutics·2025· 1 citedOpen Access
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A <scp>GETAID</scp> Multicentre Cohort Study
Alimentary Pharmacology & Therapeutics·2025· 7 citedOpen Access
Pochitis: management and outlook
Hépato-Gastro & Oncologie Digestive·2025
P0919 Correlation between trough levels of risankizumab and clinical and biological remission in patients with moderate to severe Crohn’s disease: a retrospective multicenter study (RISE-CD)
Journal of Crohn s and Colitis·2025
OP38 Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI)
Journal of Crohn s and Colitis·2025· 3 cited
P1233 Socio- demographic determinants of fatigue in patients with inflammatory bowel disease in remission: SOFA study
Journal of Crohn s and Colitis·2025
P0706 Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study
Journal of Crohn s and Colitis·2025Open Access
P0684 Real world experience with granulocyte and monocyte adsorptive apheresis (ADACOLUMN®) in patients with refractory inflammatory bowel disease: a retrospective observational multicenter cohort study
Journal of Crohn s and Colitis·2025Open Access
P0621 Effectiveness and Safety of Induction Therapy with Upadacitinib for the Treatment of Perianal Crohn’s Disease : Real-World Data from a GETAID Multicentre Cohort Study
Journal of Crohn s and Colitis·2025· 1 cited
P0704 A Multicenter Study Evaluating the Persistence, Effectiveness, and Safety of Methotrexate in Patients with Inflammatory Bowel Disease: The MICI-METHO Study
Journal of Crohn s and Colitis·2025· 1 cited
P1056 Effectiveness and Safety of Upadacitinib Induction Therapy in Real-World Setting for 234 Patients with Crohn’s Disease: A GETAID Multicentre Cohort Study
Journal of Crohn s and Colitis·2025
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
The Lancet·2024· 62 citedOpen Access
Upadacitinib for orofacial granulomatosis associated with Crohn's disease
Journal of the European Academy of Dermatology and Venereology·2024· 2 cited
page 1 of 11Next →

Frequent Co-authors

David Laharie(33), Laurent Peyrin‐Biroulet(32), Stéphane Nancey(30), Mathurin Fuméry(28), Aurélien Amiot(27), Guillaume Bouguen(24), Maria Nachury(23), Lucine Vuitton(23), Yoram Bouhnik(22), Véred Abitbol(22), Anthony Buisson(21), Xavier Roblin(19), Stéphanie Viennot(19), Mélanie Serrero(19), Cyrielle Gilletta(18), Matthieu Allez(17), Guillaume Savoye(16), Xavier Hébuterne(13), Jérôme Filippi(13), Anne Bourrier(11)